Atlas Capital Advisors LLC Incyte Corp Transaction History

Atlas Capital Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$63.34 - $74.11 $2,533 - $2,964	-40 Reduced 40.0%	60 $4.4 Million
Q3 2021 Oct 28, 2021	BUY	$68.67 - $84.02 $3,433 - $4,201	50 Added 100.0%	100 $0
Q1 2021 May 10, 2021	BUY	$76.02 - $100.5 $3,801 - $5,025	50 New	50 $0
Q1 2020 May 04, 2020	SELL	$63.18 - $85.97 $101,340 - $137,895	-1,604 Closed	0 $0
Q4 2019 Jan 28, 2020	BUY	$73.04 - $95.72 $6,354 - $8,327	87 Added 5.74%	1,604 $0
Q3 2019 Nov 01, 2019	BUY	$72.82 - $86.52 $110,467 - $131,250	1,517 New	1,517 $0

649

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Capital Advisors LLC with notifications on news.